Different stocks. Same technical structure.

Haven’t we seen this before?👀

Helus Pharma Inc. (NASDAQ: HELP) is showing striking technical similarities to Moderna (NASDAQ: MRNA), from their long-term bearish channels to their breakout structures.

MRNA has already surged approximately 451% in the measured move on our chart, while HELP appears to be at an earlier stage of a similar setup.📈

Could history be repeating itself?

📊 Technical Outlook - A Familiar Pattern

Let’s start with MRNA.

As discussed in our previous MRNA analysis, Moderna spent several years trading within a falling channel marked in orange, consistently forming lower highs and lower lows.

The technical picture shifted when MRNA broke above its last major high around $38, marked in blue, while reclaiming its 50-week EMA, signaling a potential bullish reversal.

What happened next?📈

MRNA surged approximately 451% in the measured move on our chart, breaking through resistance at $60, then $115, and eventually above $220 (Key Level 3).

Now, here’s where things get interesting.

HELP appears to be developing a remarkably similar technical structure.

Like MRNA, HELP spent an extended period within a falling orange channel, before establishing a potential bottom near the blue demand zone around $5.

Buyers then pushed the stock above the channel’s upper boundary and its 50-week EMA.

More importantly, HELP recently broke above its last major high marked in blue and the $10 round-number resistance (Key Level 1).

These developments suggest a potential shift from bearish to bullish, resembling MRNA’s earlier breakout structure.📈

🐂 Could HELP Follow MRNA’s Rhythm?

While MRNA has already broken above Key Level 3, HELP has only recently cleared Key Level 1.

If a similar bullish structure develops, the next resistance to monitor is $20 (Key Level 2), followed by $45 (Key Level 3) if momentum continues.🎯

Interestingly, a move from HELP’s earlier breakout region near $6.70 toward $45 represents approximately 570% hypothetical upside, compared with MRNA’s measured 451% rally. However, similar chart structures do not guarantee similar outcomes.

For now, $10 remains the key support. Holding above it would support the bullish scenario, while a sustained break below could signal a deeper correction.

🧬 Fundamental Outlook

Beyond the technical picture, Helus Pharma’s clinical developments could support our bullish scenario.

Its leading candidate, HLP003, targets major depressive disorder and has received FDA Breakthrough Therapy Designation.

In September 2026, Helus presented new clinical analyses, followed by an announcement of an October 21 investor presentation covering HLP003 and HLP004, its treatment candidate for generalized anxiety disorder.

With Phase 3 results expected in Q4 2026, positive outcomes could strengthen investor confidence and potentially support bullish momentum, although clinical risks remain. 🧬

🎯 Final Thoughts

Different stocks. Similar structures. Could this be another déjà vu moment?👀

Like MRNA, HELP is showing signs of a potential bullish reversal following several key technical breakouts.

The levels to monitor are $10 support, followed by $20 and $45 resistance.🎯

As long as $10 holds, the bullish scenario could remain intact, although future performance will depend on HELP’s price action, clinical developments, and broader market conditions.

⚠️Disclaimer: This analysis is for educational and informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. All trading and investing involve risk. Always conduct your own research and manage your exposure accordingly.